Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.
Also called NCT05735197
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 100 participants
- Sponsor
- Registry
-
NCT05735197
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Egypt
- Registry status
- Completed
Technical summary
Registry record NCT05735197. Randomized; single masking; primary purpose prevention. Start 2022-09-01 (actual); primary completion 2023-08-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients
- Condition
- Chronic Kidney Diseases
- Condition
- Bone Diseases, Metabolic
- Intervention (Drug)
- Dapagliflozin 10mg Tab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Mansoura University
Record details
- Record id
cardio:ct-nct05735197- Content hash
dd2ee625cce7580fe97eba092e5eee024d656b86e70127c475fa9588545f0877